Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors

Next Previous
Search
Trial Profile

A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eganelisib (Primary) ; Nivolumab (Primary)
  • Indications Adrenocortical carcinoma; Advanced breast cancer; Carcinoma; Head and neck cancer; HER2 negative breast cancer; Malignant melanoma; Mesothelioma; Mouth neoplasm; Nasopharyngeal cancer; Non-small cell lung cancer; Pharyngeal neoplasms; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms MARIO-1
  • Sponsors Infinity Pharmaceuticals

    • Most Recent Events

    • 10 Jul 2023 According to an Infinity Pharmaceuticals media release, data from this trial can be viewed as webcast on Infinity's website which can be located at www.infi.com under the Investor/Media tab in the Events and Presentations folder.
    • 13 Apr 2023 According to an Infinity Pharmaceuticals media release, translational data indicating increased expression of the TGF-beta activating integrin alphaVbeta8 in head and neck squamous cell cancer patients treated with combination of eganelisib and nivolumab will be presented at the 2023 Annual Meeting of the American Association of Cancer Research (AACR) to be held April 14 - 19, 2023 in Orlando, Florida.
    • 01 Apr 2022 Planned End Date changed from 1 Oct 2022 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top